The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (doi:10.7910/DVN/DJ054F)

View:

Part 1: Document Description
Part 2: Study Description
Part 5: Other Study-Related Materials
Entire Codebook

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants

doi:10.7910/DVN/DJ054F

Harvard Dataverse

2021-06-09

1

Scott, J. Anthony G.; Gallagher, Katherine, 2021, "The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants", https://doi.org/10.7910/DVN/DJ054F, Harvard Dataverse, V1

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants

doi:10.7910/DVN/DJ054F

Scott, J. Anthony G. (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya & London School of Hygiene and Topical Medicine)

Gallagher, Katherine (London School of Hygiene and Tropical Medicine)

Harvard Dataverse

Scott, J. Anthony G.

Gallagher, Katherine

Scott, J. Anthony G.

2021-04-16

Medicine, Health and Life Sciences

<p>Before the introduction of pneumonia vaccines in 2000, between 700,000 - 1 million children died each year as a result of infection with the bacteria Streptococcus pneumoniae and the resulting diseases, namely, meningitis, sepsis and pneumonia. Most of the deaths were in Africa and Asia. Where the vaccines have been introduced, they have been highly effective and have already reduced disease. However, at 10 USD per child, they are not affordable to most low-income countries without financial support from Gavi, the Vaccine Alliance.</p> <p>This project aims to assess whether lower doses of the two commercially available pneumonia vaccines can protect Kenyan infants as well as the full dose. The results could be used to increase the affordability of the pneumonia vaccine, and enable delivery of the vaccine to continue in the absence of Gavi support.</p> <p>The trial is registered on ClinicalTrials.gov - <a href="https://clinicaltrials.gov/ct2/show/NCT03489018">NCT03489018</a></p> <p>This data package includes: <ol> <li> Study Protocol</li> </ol> </p>

<p><strong>Data Access: </strong> Restricted</p> <p>Access to these data requires submission of a formal request for consideration by our Data Governance Committee. </p> <strong>How to request</strong> <ol> <li>Download and complete the <a href="https://kemri-wellcome.org/zp-content/uploads/2021/02/KWTRP_Dataverse_Data_Request_Form_2019.docx"><strong>data request form</strong></a></li> <li> Email completed data request form to the Data Governance Committee at <a href="mailto:dgc@kemri-wellcome.org?cc=lmwango@kemri-wellcome.org?Subject=Data%20Access%20Request"><strong>dgc@kemri-wellcome.org</strong></a> </li> </ol> <p><strong>License: </strong> <a href="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</a> <a href="https://creativecommons.org/licenses/by/4.0/legalcode"><img src="https://i.creativecommons.org/l/by/3.0/88x31.png"> </a></p>

<p>Publications based on this data collection should acknowledge this source by means of bibliographic citation.</p>

<p>This data is licensed under the <a href="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</a> <a href="https://creativecommons.org/licenses/by/4.0/legalcode"><img src="https://i.creativecommons.org/l/by/3.0/88x31.png"> </a> </p>

For access to more detailed information beyond the metadata and documentation provided, please send a signed data request form to [<a href="mailto:dgc@kemri-wellcome.org">dgc@kemri-wellcome.org</a> ]. <strong> <a href="https://kemri-wellcome.org/zp-content/uploads/2021/02/KWTRP_Dataverse_Data_Request_Form_2019.docx">Click to download Data Request Form</a></strong>

Label:

Protocol_PCVFractionaldose_v.6.0_01Apr20 clean.pdf

application/pdf